Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
GOUT
MCID: GT001
MIFTS: 61

Gout (GOUT)

Categories: Blood diseases, Bone diseases, Nephrological diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Gout

About this section

MalaCards integrated aliases for Gout:

Name: Gout 12 76 25 37 55 6 43 3 44 15 63 73
Arthritis, Gouty 25 44 73
Gouty Arthritis 12 25 15
Gouty Arthropathy 12 25
Articular Gout 12 25
Arthritis Gouty 55

Classifications:

MalaCards categories:
Anatomical: Bone diseases Nephrological diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:13189
NCIt 50 C34650
SNOMED-CT 68 48440001 90560007
KEGG 37 H01532
Sources

Summaries for Gout

About this section
MedlinePlus : 43 Gout is a common, painful form of arthritis. It causes swollen, red, hot and stiff joints. Gout happens when uric acid builds up in your body. Uric acid comes from the breakdown of substances called purines. Purines are in your body's tissues and in foods, such as liver, dried beans and peas, and anchovies. Normally, uric acid dissolves in the blood. It passes through the kidneys and out of the body in urine. But sometimes uric acid can build up and form needle-like crystals. When they form in your joints, it is very painful. The crystals can also cause kidney stones. Often, gout first attacks your big toe. It can also attack ankles, heels, knees, wrists, fingers, and elbows. At first, gout attacks usually get better in days. Eventually, attacks last longer and happen more often. You are more likely to get gout if you Are a man Have family member with gout Are overweight Drink alcohol Eat too many foods rich in purines Gout can be hard to diagnose. Your doctor may take a sample of fluid from an inflamed joint to look for crystals. You can treat gout with medicines. Pseudogout has similar symptoms and is sometimes confused with gout. However, it is caused by calcium phosphate, not uric acid. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Gout, also known as arthritis, gouty, is related to hyperuricemic nephropathy, familial juvenile, 1 and kelley-seegmiller syndrome, and has symptoms including back pain, sciatica and muscle cramp. An important gene associated with Gout is DARS2 (Aspartyl-TRNA Synthetase 2, Mitochondrial), and among its related pathways/superpathways are Purine metabolism and Purine metabolism (KEGG). The drugs Liraglutide and Colchicine have been mentioned in the context of this disorder. Affiliated tissues include joint, kidney and bone, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 An arthritis that has material basis in uric acid crystal deposits located in joint.

Genetics Home Reference : 25 Gout is a type of arthritis, which is a group of related disorders caused by episodes of abnormal inflammation in the joints. People with gout have high levels of a substance called urate in the blood (hyperuricemia). Gout develops when hyperuricemia leads to the formation of urate crystals in joints, triggering an inflammatory response from the immune system.

PubMed Health : 63 About gout: Gout is a metabolic disorder which causes inflammation of the joints. During acute episodes, certain joints swell up within just a few hours and become very sensitive to pain. The inflammation is triggered by tiny needle-shaped crystals of uric acid that mainly build up in the joints. These crystals may form if there is too much uric acid in the body. The inflammation normally goes away on its own within one to two weeks. The pain can be relieved with medication.Most people with gout experience acute attacks every now and then. Months or even years can pass between attacks, but they may be more frequent too. There are a number of options to prevent them. Some people already notice an improvement if they avoid certain foods and other possible triggers. Others may take medication to lower their uric acid levels over the long term. The medication is mostly considered for people who have frequent gout attacks or complications such as kidney stones or lumps called tophi.Many people have high levels of uric acid without it causing any noticeable problems. It's not clear whether this affects their health. It doesn't need to be treated.

Wikipedia : 76 Gout is a form of inflammatory arthritis characterized by recurrent attacks of a red, tender, hot, and... more...

Sources

Related Diseases for Gout

About this section

Diseases related to Gout via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 231)
# Related Disease Score Top Affiliating Genes
1 hyperuricemic nephropathy, familial juvenile, 1 33.3 HPRT1 SLC22A12 UMOD
2 kelley-seegmiller syndrome 33.3 APRT HPRT1
3 phosphoribosylpyrophosphate synthetase superactivity 33.1 HPRT1 PRPS1
4 lesch-nyhan syndrome 32.5 ADSL APRT HPRT1 XDH
5 hyperuricemia 30.8 ABCG2 HPRT1 SLC17A1 SLC17A3 SLC22A12 SLC2A9
6 hereditary xanthinuria 29.9 APRT XDH
7 adenine phosphoribosyltransferase deficiency 29.8 APRT HPRT1 XDH
8 nephrolithiasis 29.8 APRT HPRT1 SLC22A12 SLC2A9 UMOD XDH
9 xanthinuria 29.1 ADSL APRT HPRT1 SLC22A12 SLC2A9 XDH
10 uric acid concentration, serum, quantitative trait locus 1 11.8
11 arthritis 11.4
12 crystal arthropathies 11.3
13 autosomal dominant tubulointerstitial kidney disease 11.3
14 chondrocalcinosis 2 11.3
15 uric acid concentration, serum, quantitative trait locus 4 11.1
16 medullary cystic kidney disease 2 11.0
17 nephronophthisis-like nephropathy 1 11.0
18 autosomal dominant tubulointerstitial kidney disease, umod-related 11.0
19 uromodulin-associated kidney disease 11.0
20 occipital neuralgia 11.0
21 rheumatoid arthritis 10.3
22 chondrocalcinosis 10.3
23 kidney disease 10.3
24 chronic kidney failure 10.3
25 nephrolithiasis, uric acid 10.2 HPRT1 XDH
26 osteoarthritis 10.2
27 myocardial infarction 10.2
28 septic arthritis 10.2
29 hypouricemia, renal, 1 10.2 HPRT1 SLC22A12 SLC2A9
30 impotence 10.2
31 enthesopathy 10.2
32 acute urate nephropathy 10.1 CARMIL1 SLC22A12
33 vulvar vestibulitis syndrome 10.1 IL1B NLRP3
34 arthropathy 10.1
35 familial cold autoinflammatory syndrome 1 10.1 IL1B NLRP3
36 cervical adenitis 10.1 IL1B NLRP3
37 popliteal cyst 10.1
38 schnitzler syndrome 10.1 IL1B NLRP3
39 dupuytren contracture 10.1 IL1B XDH
40 chronic recurrent multifocal osteomyelitis 10.0 IL1B NLRP3
41 carpal tunnel syndrome 10.0
42 mononeuropathy of the median nerve, mild 10.0
43 bursitis 10.0
44 depression 10.0
45 xanthinuria, type i 10.0 APRT UMOD XDH
46 nephrolithiasis, calcium oxalate 10.0 APRT UMOD XDH
47 body mass index quantitative trait locus 1 10.0
48 osteoporosis 9.9
49 psoriatic arthritis 9.9
50 glycogen storage disease 9.9

Comorbidity relations with Gout via Phenotypic Disease Network (PDN): (show all 27)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Aortic Valve Disease 1
Benign Essential Hypertension Bladder Neck Obstruction
Bronchitis Chronic Kidney Failure
Chronic Myocardial Ischemia Deficiency Anemia
Familial Atrial Fibrillation First-Degree Atrioventricular Block
Generalized Atherosclerosis Heart Disease
Hypertension, Essential Hypothyroidism
Intermediate Coronary Syndrome Iron Deficiency Anemia
Ischemic Heart Disease Kidney Disease
Mitral Valve Disease Osteoarthritis
Peripheral Vascular Disease Prostate Cancer
Prostatic Hypertrophy Sinoatrial Node Disease
Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Gout:



Diseases related to Gout
Sources

Symptoms & Phenotypes for Gout

About this section

UMLS symptoms related to Gout:


back pain, sciatica, muscle cramp

GenomeRNAi Phenotypes related to Gout according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 10 PRPS1
2 Decreased viability GR00240-S-1 10 ABCG2 ADSL
3 Decreased viability GR00402-S-2 10 ABCG2 ADSL ALDH16A1 ALDH2 APRT CARMIL1
4 no effect GR00402-S-1 9.6 ABCG2 ADSL ALDH16A1 ALDH2 APRT CARMIL1

MGI Mouse Phenotypes related to Gout:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10 ABCG2 ALDH16A1 ALDH2 APRT HPRT1 IL1B
2 integument MP:0010771 9.7 ABCG2 ALDH2 APRT HPRT1 IL1B NLRP3
3 mortality/aging MP:0010768 9.7 ADSL ALDH2 APRT DARS2 HPRT1 IL1B
4 renal/urinary system MP:0005367 9.28 ABCG2 ALDH2 APRT HPRT1 NLRP3 SLC22A12
Sources

Drugs & Therapeutics for Gout

About this section

PubMedHealth treatment related to Gout: 63

The treatment of gout has two aims:In the short term, it should provide pain relief during gout attacks.In the long term, it should prevent further attacks and lower the risk of chronic inflammations and joint damage.Gout attacks are treated with anti-inflammatory medications. These includeanti-inflammatory painkillers, such as ibuprofen, indometacine or naproxen,steroid medicines (usually tablets with prednisolone), as well asthe gout medicine colchicine. Because colchicine is slow to start working and has certain possible side effects, it is no longer used very often.If a single drug can’t provide enough pain relief, the treatments can be combined. Cooling the affected joint probably also helps, and most people find it very soothing.The goal of long-term gout treatment is to prevent gout attacks and complications by lowering the level of uric acid. This can be done in two ways:Changing your diet: Especially eating less meat, fish and seafood, and drinking less alcohol.Taking medication to lower your uric acid levels, typically allopurinol.Not everyone who has gout needs to take medicine to lower their uric acid levels. In particular, people who have already had a gout attack usually don’t need to take it. This is because some people don't have any problems after that for years, and others only have them rarely.Medication is mainly used if the attacks become more frequent or are very distressing. It also makes sense to take it if complications such as tophi or kidney stones have already developed, or if the functioning of the kidney is affected. Medication might also be an option if changes to your diet aren’t enough to make a difference.

Drugs for Gout (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 678)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Liraglutide Approved Phase 4 204656-20-2 44147092
2
Colchicine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 64-86-8 6167 2833
3
Allopurinol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 315-30-0 2094
4
Naproxen Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22204-53-1 1302 156391
5
Ibuprofen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15687-27-1 3672
6
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 73590-58-6 4594
7
Indomethacin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 53-86-1 3715
8
Resveratrol Approved, Experimental, Investigational Phase 4 501-36-0 445154
9
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 169590-42-5 2662
10
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 161796-78-7, 119141-88-7 4594 9579578
11
Tramadol Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 27203-92-5 33741
12
Codeine Approved, Illicit Phase 4,Phase 2,Phase 3 76-57-3 5284371
13
Acetaminophen Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 103-90-2 1983
14
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 93-14-1 3516
15 Orange Approved Phase 4,Phase 1
16
Febuxostat Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 144060-53-7 134018
17
Diclofenac Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 15307-86-5 3033
18
Probenecid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 57-66-9 4911
19
Rasburicase Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 134774-45-1
20
Nitric Oxide Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 10102-43-9 145068
21
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 76-42-6 5284603
22 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1
23
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 94-09-7, 1994-09-7 2337
24
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1 51-61-6, 62-31-7 681
25
Sumatriptan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 103628-46-2 5358
26
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-28-2 5757
27
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 28014-46-2
28 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 979-32-8
29
Ketorolac Approved Phase 4,Phase 3,Not Applicable 66635-83-4, 74103-06-3 3826
30
Lidocaine Approved, Vet_approved Phase 4,Not Applicable 137-58-6 3676
31
Acetylcysteine Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 616-91-1 12035
32
Nifedipine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 21829-25-4 4485
33
Etoricoxib Approved, Investigational Phase 4,Phase 3 202409-33-4 123619
34
Lumiracoxib Approved, Investigational Phase 4 220991-20-8 151166
35
Olmesartan Approved, Investigational Phase 4 144689-63-4, 144689-24-7 158781 130881
36
Angiotensin II Approved, Investigational Phase 4,Phase 2,Phase 3 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
37
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
38
Theophylline Approved Phase 4,Phase 1 58-55-9 2153
39
Coal tar Approved Phase 4,Phase 3 8007-45-2
40
Ranibizumab Approved Phase 4 347396-82-1 459903
41
Orphenadrine Approved Phase 4 83-98-7 4601
42
Methocarbamol Approved, Vet_approved Phase 4 532-03-6 4107
43
Hydrocodone Approved, Illicit, Investigational Phase 4,Not Applicable 125-29-1 5284569
44
Ropivacaine Approved Phase 4 84057-95-4 175805 71273
45
Morphine Approved, Investigational Phase 4 57-27-2 5288826
46
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
47
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
48
Tranexamic Acid Approved Phase 4 1197-18-8 5526
49
Copper Approved, Investigational Phase 4 7440-50-8 27099
50
Potassium Citrate Approved, Investigational, Vet_approved Phase 4

Interventional clinical trials:

(show top 50) (show all 897)
# Name Status NCT ID Phase Drugs
1 Effect of Victoza on Dietary Preferences and Habit in Patients With Type 2 Diabetes Unknown status NCT02674893 Phase 4 Liraglutide
2 Post-MI PET Scan Imaging of Inflammation Unknown status NCT02281305 Phase 4 Colchicine
3 Colchicine in ST-elevation Myocardial Infarction Unknown status NCT01936285 Phase 4 Colchicine 2 mg loading dose; 0.5 mg bid for 5 days;Placebo
4 Colchicine for Acute Coronary Syndromes Unknown status NCT01906749 Phase 4 Colchicine;Placebo
5 Investigation of the Atherogenic Effects of Uric Acid-modified in Endothelial Dysfunction and the the Preventional Mechanism by Anthocyanidines Unknown status NCT02797028 Phase 4 Allopurinol
6 Placebo In Chronic Back Pain (Phase 2) Unknown status NCT02986334 Phase 4 Naproxen;Omeprazole;Placebo
7 COX-2 Inhibitor to Prevent Post-ERCP Pancreatitis Unknown status NCT02964403 Phase 4 Cox-2;Indomethacin
8 Oral Resveratrol to Prevent Post-ERCP Pancreatitis Unknown status NCT02947932 Phase 4 Resveratrol;Indomethacin
9 Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis Unknown status NCT02355236 Phase 4 Naproxen/Esomeprazol 500/20mg;Celecoxib 200mg;Naxozol-Placebo;Comparator-Placebo
10 Postoperative Analgesia in Laminectomy Unknown status NCT02255955 Phase 4 550 mg naproxen sodium and 30mg codeine;300 mg paracetamol and 30 mg codeine;placebo tablet
11 Efficacy of Intravenous Naproksen Sodium+Codein and Paracetamol+Codein on Postoperative Pain on Postoperative Pain Unknown status NCT02252614 Phase 4 naproxen sodium codein;paracetamol codein;Placebo
12 Naproxen for Acute Pain After Surgery: A Randomized, Placebo-Controlled Trial Unknown status NCT00615875 Phase 4 naproxen;placebo
13 Does Allopurinol Prolong a Treated, Acute Gout Flare? Completed NCT01988402 Phase 4 allopurinol;Placebo (sugar pill)
14 Initiation of Allopurinol at First Medical Contact for Acute Attacks of Gout Completed NCT01310673 Phase 4 Allopurinol;Placebo
15 Immune Molecular and Inflammatory Cytokines Dysfunction Analysis in Gout Patients With Different Urate Levels Completed NCT02060552 Phase 4 Diacerein;Colchicine;Febuxostat
16 Efficacy and Safety of Colchicine for the Prevention of Gout Flares During the Initiation of Allopurinol Completed NCT01451645 Phase 4 Colchicine (Colcrys®);placebo;allopurinol
17 Colchicine Or Naproxen Treatment for ACute gouT Completed NCT01994226 Phase 4 Low-dose colchicine;Naproxen 750 mg/250 mg
18 An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels. Completed NCT01112982 Phase 4 Febuxostat;Colchicine
19 A Study Evaluating the Effect of Etoricoxib and Indomethacin in the Treatment of Acute Gout (0663-081)(COMPLETED) Completed NCT00142558 Phase 4 MK0663; etoricoxib / Duration of Treatment: 5 Days;Comparator: indomethacin 75 mg sustained release capsule / Duration of Treatment: 5 Days
20 Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout Completed NCT02500641 Phase 4 Febuxostat 80/120mg/day;Allopurinol 100 up to 600mg/day;Colchicine;Naproxen;Omeprazole
21 Allopurinol Outcome Study Completed NCT01391325 Phase 4 Allopurinol
22 Efficacy and Safety of Lumiracoxib 400 mg Once Daily in Acute Flares of Gout Completed NCT00170781 Phase 4 Lumiracoxib
23 Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome Completed NCT01654276 Phase 4 Febuxostat
24 Optimal Administration of Allopurinol in Dialysis Patients Completed NCT02477488 Phase 4 Allopurinol
25 Zurig (Febuxostat) 40mg Efficacy and Safety Trial Completed NCT02600780 Phase 4 Febuxostat;Allopurinol
26 Study of Febuxostat Effect on Blood Pressure in Patients With High Normal Blood Pressure Completed NCT01472692 Phase 4 Febuxostat
27 Mechanistic Effects of Colchicine in Patients With Myocardial Infarction Completed NCT02995512 Phase 4 Colchicine 0.6 mg tablets
28 Postmarketing Study to Determine Performance of the SIGMA HP® PARTIAL KNEE SYSTEM Completed NCT01529099 Phase 4
29 Do Xanthine Oxidase Inhibitors Reduce Both Left Ventricular Hypertrophy and Endothelial Dysfunction in Cardiovascular Patients With Renal Dysfunction? Completed NCT00688480 Phase 4 Placebo;Allopurinol
30 Drug Interaction Study of Olmesartan in Healthy Chinese Volunteers Completed NCT01907373 Phase 4 olmesartan medoxomil;olmesartan medoxomil+probenecid
31 Does ALlopurinol Regress lefT Ventricular Hypertrophy in End Stage REnal Disease: The ALTERED Study Completed NCT01951404 Phase 4 Allopurinol;Placebo (for allopurinol)
32 The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Participants With Chronic Stable Angina Completed NCT01763996 Phase 4 Febuxostat;Febuxostat placebo
33 Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS) Completed NCT01328769 Phase 4 Febuxostat;Placebo
34 Fasturtec TLS Treatment / Prophylysis Completed NCT00651911 Phase 4 urate oxidase
35 Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome Completed NCT00563771 Phase 4 Rasburicase
36 Rasburicase in Tumor Lysis Syndrome Completed NCT00302653 Phase 4 Rasburicase
37 Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy Completed NCT00230217 Phase 4 Rasburicase (SR29142)
38 The Effect of Uric Acid Lowering in Type 1 Diabetes Completed NCT02344602 Phase 4 Febuxostat
39 Efficacy of Proprietary Cherry Juice Blend in Osteoarthritis of the Knee Completed NCT00443092 Phase 4
40 Treatment of Hyperuricemia in Patients With Heart Failure Completed NCT00422318 Phase 4 Benzbromarone (drug)
41 Diuretics In the Management of Essential Hypertension (DIME) Study Completed NCT00131846 Phase 4 Thiazide diuretics;No diuretics
42 The Comparison of the Efficacy of Once and Twice Daily Colchicine Dosage in Pediatric Patients With FMF Completed NCT02602028 Phase 4 colchicine
43 Anti-platelet Effects of Colchicine in Healthy Volunteers Completed NCT02140372 Phase 4 Colchicine
44 Colchicine in Coronary Artery Bypass Graft (CABG) Completed NCT02122484 Phase 4 Colchicine
45 Drug Interaction Study of Colchicine and Theophylline Completed NCT01601132 Phase 4 theophylline;colchicine
46 Cochicine Treatment for Post- Operative Pericardial Effusion Completed NCT01266694 Phase 4 Colchicines;Placebo
47 A Pilot Study for PK/PD Parameter of Colchicine in Chronic Kidney Disease Patient. Completed NCT01173107 Phase 4 colchicine
48 Healthy and Renal Impairment Study of Colcrys (Colchicine, USP) Completed NCT01084278 Phase 4 Colchicine
49 Thiocolchicoside Injection and Capsule in Treatment of Acute Low Back Pain Completed NCT00917436 Phase 4 Thiocolchicoside
50 EMINEM: Efficacy of Muscoril In NEck Myofascial Syndromes Completed NCT00272532 Phase 4 Thiocolchicoside

Search NIH Clinical Center for Gout

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: gout

Sources

Genetic Tests for Gout

About this section
Sources

Anatomical Context for Gout

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Gout:

19
Joint

MalaCards organs/tissues related to Gout:

41
Kidney, Bone, Liver, Skin, Heart, Testes, Endothelial
Sources

Publications for Gout

About this section

Articles related to Gout:

(show top 50) (show all 2012)
# Title Authors Year
1
The Challenges of Approaching and Managing Gout. ( 30447743 )
2019
2
Burden of gout in the Nordic region, 1990-2015: findings from the Global Burden of Disease Study 2015. ( 29376465 )
2018
3
Gout: A Disease of Kings. ( 29393108 )
2018
4
Isolation and genomic characterization of gosling gout caused by a novel goose astrovirus. ( 29920970 )
2018
5
Correction: <i>An update on the management of gout</i>. ( 29980592 )
2018
6
Paraparesis revealing tophaceous gout. ( 29409109 )
2018
7
Genetic characterization of a new astrovirus in goslings suffering from gout. ( 29980852 )
2018
8
Next-generation sequencing profiling of mitochondrial genomes in gout. ( 29976239 )
2018
9
Synovial fluid uric acid level aids diagnosis of gout. ( 29930806 )
2018
10
Management of hyperuricemia and gout in obese patients undergoing bariatric surgery. ( 29888674 )
2018
11
Prevalence and characteristics of metabolic syndrome in gout patients in a hospital setting in sub-Saharan Africa. ( 29980454 )
2018
12
Lesinurad/Allopurinol (Duzallo) for Gout-Associated Hyperuricemia. ( 29318274 )
2018
13
Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout. ( 29931553 )
2018
14
Correction to: Retinal complications of gout: a case report and review of the literature. ( 29402259 )
2018
15
Study on the expressions of NLRP3 gene transcript variants in peripheral blood monocytes of primary gout patients. ( 29946988 )
2018
16
Keeping Up with the Applications: Lessons Learned Evaluating Gout Apps. ( 29969385 )
2018
17
Chronic gout: Barriers to effective management. ( 29966174 )
2018
18
A common variant of MAF/c-MAF, transcriptional factor gene in the kidney, is associated with gout susceptibility. ( 29080939 )
2018
19
Management of gout and hyperuricemia: Multidisciplinary consensus in Taiwan. ( 29363262 )
2018
20
Association of gout with osteoporotic fractures. ( 29955945 )
2018
21
Improved Gout Outcomes in Primary Care Using a Novel Disease Management Program: A Pilot Study. ( 29438607 )
2018
22
Hypouricaemic effects of yogurt containing Lactobacillus gasseri PA-3 in patients with hyperuricaemia and/or gout: a randomized, double-blind, placebo-controlled study. ( 29446654 )
2018
23
Gout and arrhythmias: In search for causation beyond association. ( 29937218 )
2018
24
Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions for disease elements in gout. ( 29799677 )
2018
25
Advanced Imaging in the Diagnosis of Gout and Other Crystal Arthropathies. ( 29672810 )
2018
26
Impaired arterial responsiveness in untreated gout patients compared with healthy non-gout controls: association with serum urate and C-reactive protein. ( 29450849 )
2018
27
Managing Gout in the Patient with Renal Impairment. ( 29435850 )
2018
28
Gout drugs use and risk of cancer: A case-control study. ( 29427783 )
2018
29
Health-related quality of life in gout in primary care: Baseline findings from a cohort study. ( 29398125 )
2018
30
From hyperuricaemia to gout: what are the missing links? ( 29921940 )
2018
31
Assessing qualitatively the impact of gout on sleep: any sleep was a dream far away until the gout flare resolved. ( 29947811 )
2018
32
The diagnostic performance of musculoskeletal ultrasound in gout: A systematic review and meta-analysis. ( 29979706 )
2018
33
Metabolomics approach by <sup>1</sup>H NMR spectroscopy of serum reveals progression axes for asymptomatic hyperuricemia and gout. ( 29871692 )
2018
34
Gout as a risk factor for osteoporosis: epidemiologic evidence from a population-based longitudinal study involving 108,060 individuals. ( 29383389 )
2018
35
Lumbar Gout Tophus Mimicking Epidural Abscess with Magnetic Resonance Imaging, Bone, and Gallium Scans. ( 29643682 )
2018
36
Upper Extremity Compartment Syndrome in a Patient with Acute Gout Attack but without Trauma or Other Typical Causes. ( 29796328 )
2018
37
Coexisting Gout and Chondrocalcinosis on Hand Radiograph. ( 29717094 )
2018
38
Obesity, hypertension and diuretic use as risk factors for incident gout: a systematic review and meta-analysis of cohort studies. ( 29976236 )
2018
39
Mediation analysis to understand genetic relationships between habitual coffee intake and gout. ( 29976226 )
2018
40
The Cost-effectiveness of Biannual Serum Urate (SU) Monitoring after Reaching Target in Gout: A Health Economic Analysis Comparing SU Monitoring. ( 29449500 )
2018
41
Hospitalization Increases the Risk of Acute Arthritic Flares in Gout: A Population-based Study over 2 Decades. ( 29961683 )
2018
42
Management of gout by UK rheumatologists: a British Society for Rheumatology national audit. ( 29447370 )
2018
43
Spinal gout causing reversible quadriparesis: a case report and literature review. ( 29915646 )
2018
44
Anorexia nervosa and uric acid beyond gout: An idea worth researching. ( 29314231 )
2018
45
Ancient herbal component may be a novel therapeutic for gouty arthritis. ( 30517770 )
2018
46
Anti-hyperuricemic and anti-gouty arthritis activities of polysaccharide purified from Lonicera japonica in model rats. ( 30445085 )
2018
47
Diagnostic accuracy of dual-energy computed tomography and joint aspiration: a prospective study in patients with suspected gouty arthritis. ( 30418110 )
2018
48
Joint Clinical Consensus Statement of the American College of Foot and Ankle Surgeons® and the American Association of Nurse Practitioners®: Etiology, Diagnosis, and Treatment Consensus for Gouty Arthritis of the Foot and Ankle. ( 30368431 )
2018
49
Coexisting polyarticular septic arthritis, gout and pseudogout. ( 30373898 )
2018
50
Trans-Chalcone Attenuates Pain and Inflammation in Experimental Acute Gout Arthritis in Mice. ( 30333752 )
2018
Sources

Variations for Gout

About this section

ClinVar genetic disease variations for Gout:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 DARS2 NM_018122.4(DARS2): c.228-21_228-20delTTinsC indel Pathogenic rs367543010 GRCh37 Chromosome 1, 173797450: 173797451
2 DARS2 NM_018122.4(DARS2): c.228-21_228-20delTTinsC indel Pathogenic rs367543010 GRCh38 Chromosome 1, 173828312: 173828313
3 DARS2 NM_018122.4(DARS2): c.492+2T> C single nucleotide variant Pathogenic rs142433332 GRCh37 Chromosome 1, 173800770: 173800770
4 DARS2 NM_018122.4(DARS2): c.492+2T> C single nucleotide variant Pathogenic rs142433332 GRCh38 Chromosome 1, 173831632: 173831632
Sources

Expression for Gout

About this section
Search GEO for disease gene expression data for Gout.
Sources

Pathways for Gout

About this section

Pathways related to Gout according to KEGG:

37
# Name Kegg Source Accession
1 Purine metabolism hsa00230

Pathways related to Gout according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Purine metabolism (KEGG) 1
Show member pathways
 12.22 ADSL APRT HPRT1 PRPS1 XDH
2
Purine metabolism (REACTOME) 1
Show member pathways
 11.96 ADSL APRT HPRT1 XDH
3
Antifolate resistance 37
10.92 ABCG2 IL1B
4
IL1 and megakaryocytes in obesity 1
10.8 IL1B NLRP3
5
Thiopurine Pathway, Pharmacokinetics/Pharmacodynamics 61
10.76 HPRT1 PRPS1 XDH
6
Zidovudine Pathway, Pharmacokinetics/Pharmacodynamics 61
10.67 ABCG2 SLC22A11
7
Nucleotide Metabolism 1
10.41 ADSL HPRT1 PRPS1
8
Uricosurics Pathway, Pharmacodynamics 61
10.18 ABCG2 SLC17A1 SLC17A3 SLC22A11 SLC22A12 SLC2A9
Sources

GO Terms for Gout

About this section

Cellular components related to Gout according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.56 ALDH2 APRT CARMIL1 HPRT1 IL1B SLC22A11
2 apical plasma membrane GO:0016324 9.17 ABCG2 SLC17A1 SLC17A3 SLC22A11 SLC22A12 SLC2A9

Biological processes related to Gout according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 transmembrane transport GO:0055085 9.7 ABCG2 SLC16A9 SLC17A1 SLC17A3 SLC22A11 SLC22A12
2 positive regulation of p38MAPK cascade GO:1900745 9.57 IL1B XDH
3 drug transmembrane transport GO:0006855 9.56 ABCG2 SLC17A3
4 grooming behavior GO:0007625 9.55 APRT HPRT1
5 purine-containing compound salvage GO:0043101 9.54 APRT HPRT1
6 organic anion transport GO:0015711 9.52 SLC17A3 SLC22A11
7 phosphate ion transport GO:0006817 9.51 SLC17A1 SLC17A3
8 nucleoside metabolic process GO:0009116 9.5 APRT HPRT1 PRPS1
9 sialic acid transport GO:0015739 9.49 SLC17A1 SLC17A3
10 ribonucleoside monophosphate biosynthetic process GO:0009156 9.48 ADSL PRPS1
11 interleukin-1 beta production GO:0032611 9.46 IL1B NLRP3
12 purine ribonucleoside salvage GO:0006166 9.43 APRT HPRT1
13 purine nucleotide biosynthetic process GO:0006164 9.43 ADSL HPRT1 PRPS1
14 adenine metabolic process GO:0046083 9.4 APRT HPRT1
15 adenine salvage GO:0006168 9.37 APRT HPRT1
16 urate transport GO:0015747 9.26 SLC17A1 SLC17A3 SLC22A12 SLC2A9
17 urate metabolic process GO:0046415 9.23 ABCG2 CARMIL1 SLC16A9 SLC17A1 SLC17A3 SLC22A11

Molecular functions related to Gout according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane transporter activity GO:0022857 9.54 SLC22A11 SLC22A12 SLC2A9
2 symporter activity GO:0015293 9.5 SLC16A9 SLC17A1 SLC17A3
3 oxidoreductase activity, acting on the aldehyde or oxo group of donors, NAD or NADP as acceptor GO:0016620 9.4 ALDH16A1 ALDH2
4 organic anion transmembrane transporter activity GO:0008514 9.26 SLC17A3 SLC22A11
5 drug transmembrane transporter activity GO:0015238 9.16 ABCG2 SLC17A3
6 sialic acid transmembrane transporter activity GO:0015136 8.96 SLC17A1 SLC17A3
7 urate transmembrane transporter activity GO:0015143 8.8 SLC17A3 SLC22A12 SLC2A9
Sources

Sources for Gout

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71